Failure of natalizumab to prevent relapses in neuromyelitis optica

Archives of Neurology
Ingo KleiterNeuromyelitis Optica Study Group

Abstract

To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). Retrospective case series. Neurology departments at tertiary referral centers in Germany. Patients with NMO who tested positive for antibodies to aquaporin 4. Treatment with natalizumab. Relapses and accumulation of disability. We identified 5 patients (4 female; median age, 45 years) who were initially diagnosed with MS and treated with natalizumab before diagnosis of NMO was established. Natalizumab was given as escalation therapy after failure of first- or second-line immunomodulatory therapies for MS. During natalizumab therapy (median duration, 8 infusions; range, 2-11 infusions), all 5 patients displayed persisting disease activity; a total of 9 relapses occurred (median duration to relapse, 120 days; range, 45-230 days) after the start of treatment. Four patients had an accumulation of disability and 1 patient died 2 months after cessation of natalizumab treatment. Our results suggest that natalizumab fails to control disease activity in patients with NMO. Neuromyelitis optica should be considered ...Continue Reading

Citations

Nov 22, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Ayako TasakiTakashi Kanda
May 31, 2012·Immunotherapy·Takashi Yamamura, Sachiko Miyake
Feb 20, 2014·Der Nervenarzt·J KuchlingJ Wuerfel
Jun 3, 2014·Journal of Medical Case Reports·De-Hyung LeeRalf Andreas Linker
Jul 6, 2014·Acta Neuropathologica·Olaf StüveVolker Knappertz
Aug 13, 2014·Nature Reviews. Neurology·Marios C PapadopoulosAlan S Verkman
Oct 17, 2013·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Silje Agnethe Stokke KvistadChristian A Vedeler
Aug 7, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Akiyuki UzawaSatoshi Kuwabara
Jan 12, 2013·Der Nervenarzt·B WildemannF Paul
Apr 10, 2013·Der Nervenarzt·N BorisowF Paul
May 11, 2013·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Robert Weissert
May 31, 2013·Journal of Neurology·Maciej JuryńczykKrzysztof Selmaj
Jan 1, 2014·Clinical Neurology and Neurosurgery·Silvia N Tenembaum
Apr 1, 2014·Experimental Neurology·Christopher SieMeike Mitsdoerffer
Jan 27, 2016·Journal of Neurology·Ilya AyzenbergUNKNOWN Neuromyelitis Optica Study Group
Oct 20, 2015·Journal of Neurology·Laura AzzopardiAlasdair J Coles
Nov 5, 2015·Journal of Neurology·Maciej JuryńczykJacqueline Palace
Dec 10, 2013·Physical Medicine and Rehabilitation Clinics of North America·Courtney E Francis
Jan 29, 2016·Neurology. Neuroimmunology and Neuroinflammation·Margherita NosadiniRussell C Dale
Nov 26, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ingo Kleiter, Ralf Gold
Nov 14, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stefan Bittner, Heinz Wiendl
Oct 1, 2012·Multiple Sclerosis and Related Disorders·Dorlan J KimbroughUNKNOWN GJCF-CC&BR
Dec 29, 2015·Autoimmunity Reviews·Sudarshini RamanathanFabienne Brilot
Aug 26, 2015·Journal of the Neurological Sciences·S Jarius, B Wildemann
Apr 27, 2013·Annals of the New York Academy of Sciences·Meike MitsdoerfferThomas Korn
Mar 29, 2014·Clinical and Experimental Immunology·S JariusF Paul
Jun 17, 2014·Annals of Neurology·Sarosh R IraniAngela Vincent
Jul 13, 2013·Neurological Research·Youming LongZhengqi Lu
Mar 24, 2016·Expert Review of Neurotherapeutics·Olivier Outteryck
Nov 26, 2013·Journal of Neurology·Corinna TrebstUNKNOWN Neuromyelitis Optica Study Group (NEMOS)
Apr 3, 2013·Progress in Retinal and Eye Research·Marc H LevinA S Verkman
Jun 21, 2015·Neurology·Dean M WingerchukUNKNOWN International Panel for NMO Diagnosis
Sep 25, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Maciej JuryńczykJacqueline Palace
Dec 18, 2013·Lancet Neurology·Ahmed T ToosyDavid H Miller
Nov 13, 2012·Journal of Neurology, Neurosurgery, and Psychiatry·Anu JacobJerome de Seze
Jan 31, 2014·Journal of the Neurological Sciences·Nasrin AsgariSoeren Thue Lillevang
Mar 1, 2014·Journal of the Neurological Sciences·Joanna KitleyJackie Palace
Sep 15, 2014·Clinical Therapeutics·Michael D Carrithers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.